Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.
<h4>Background</h4>Today, dementias are diagnosed late in the course of disease. Future treatments have to start earlier in the disease process to avoid disability requiring new diagnostic tools. The objective of this study is to develop a new method for the differential diagnosis and id...
Guardado en:
Autores principales: | Holger Jahn, Stefan Wittke, Petra Zürbig, Thomas J Raedler, Sönke Arlt, Markus Kellmann, William Mullen, Martin Eichenlaub, Harald Mischak, Klaus Wiedemann |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/375556f7b1884917910fff79f762f387 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Association of Clusterin Levels in Cerebrospinal Fluid with Synaptic Degeneration Across the Alzheimer’s Disease Continuum
por: Wang J, et al.
Publicado: (2020) -
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.
por: Richard J Perrin, et al.
Publicado: (2011) -
Cerebrospinal fluid research
Publicado: (2004) -
A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid.
por: Adrianna Z Herskovits, et al.
Publicado: (2013) -
Anaemia and cerebrospinal fluid biomarkers of Alzheimer’s pathology in cognitively normal elders: the CABLE study
por: Xin-Yu Yang, et al.
Publicado: (2021)